Edge Therapeutics Announces Commercial Supply Agreement for EG- 1962 with Oakwood Laboratories

Edge Therapeutics, Inc.(Nasdaq:EDGE) today announced that it has entered into a supply agreement and an amended and restated development agreement with Oakwood Laboratories for the commercial manufacturing of EG-1962 for initial product launch and thereafter. EG-1962, an orphan drug and Fast Track product designated by the U.S. Food and Drug Administration (FDA), is currently in Phase 3 development for the treatment of aneurysmal subarachnoid hemorrhage (aSAH).

This entry was posted in Recent Development News: Q3 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »